scholarly journals Microwave Breast Imaging Using Rotational Bistatic Impulse Radar for the Detection of Breast Cancer: Protocol for a Prospective Diagnostic Study (Preprint)

2019 ◽  
Author(s):  
Shinsuke Sasada ◽  
Norio Masumoto ◽  
Hang Song ◽  
Akiko Emi ◽  
Takayuki Kadoya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Breast Imaging ◽  
Molecular Subtype ◽  
Breast Tumors ◽  
Cancer Surveillance ◽  
Benign Tumors ◽  
Diagnostic Study ◽  
Imaging Device ◽  
Microwave Breast Imaging

BACKGROUND Mammography is the standard examination for breast cancer screening; however, it is associated with pain and exposure to ionizing radiation. Microwave breast imaging is a less invasive method for breast cancer surveillance. A bistatic impulse radar–based breast cancer detector has recently been developed. OBJECTIVE This study aims to present a protocol for evaluating the diagnostic accuracy of the novel microwave breast imaging device. METHODS This is a prospective diagnostic study. A total of 120 participants were recruited before treatment administration and divided into 2 cohorts: 100 patients diagnosed with breast cancer and 20 participants with benign breast tumors. The detector will be directly placed on each breast, while the participant is in supine position, without a coupling medium. Confocal images will be created based on the analyzed data, and the presence of breast tumors will be assessed. The primary endpoint will be the diagnostic accuracy, sensitivity, and specificity of the detector for breast cancer and benign tumors. The secondary endpoint will be the safety and detectability of each molecular subtype of breast cancer. For an exploratory endpoint, the influence of breast density and tumor size on tumor detection will be investigated. RESULTS Recruitment began in November 2018 and was completed by March 2020. We anticipate the preliminary results to be available by summer 2021. CONCLUSIONS This study will provide insights on the diagnostic accuracy of microwave breast imaging using a rotational bistatic impulse radar. The collected data will improve the diagnostic algorithm of microwave imaging and lead to enhanced device performance. CLINICALTRIAL Japan Registry of Clinical Trials jRCTs062180005; https://jrct.niph.go.jp/en-latest-detail/jRCTs062180005 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/17524

scholarly journals Microwave Breast Imaging Using Rotational Bistatic Impulse Radar for the Detection of Breast Cancer: Protocol for a Prospective Diagnostic Study

10.2196/17524 ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. e17524
Author(s):  
Shinsuke Sasada ◽  
Norio Masumoto ◽  
Hang Song ◽  
Akiko Emi ◽  
Takayuki Kadoya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Breast Imaging ◽  
Molecular Subtype ◽  
Breast Tumors ◽  
Cancer Surveillance ◽  
Benign Tumors ◽  
Diagnostic Study ◽  
Imaging Device ◽  
Microwave Breast Imaging

Background Mammography is the standard examination for breast cancer screening; however, it is associated with pain and exposure to ionizing radiation. Microwave breast imaging is a less invasive method for breast cancer surveillance. A bistatic impulse radar–based breast cancer detector has recently been developed. Objective This study aims to present a protocol for evaluating the diagnostic accuracy of the novel microwave breast imaging device. Methods This is a prospective diagnostic study. A total of 120 participants were recruited before treatment administration and divided into 2 cohorts: 100 patients diagnosed with breast cancer and 20 participants with benign breast tumors. The detector will be directly placed on each breast, while the participant is in supine position, without a coupling medium. Confocal images will be created based on the analyzed data, and the presence of breast tumors will be assessed. The primary endpoint will be the diagnostic accuracy, sensitivity, and specificity of the detector for breast cancer and benign tumors. The secondary endpoint will be the safety and detectability of each molecular subtype of breast cancer. For an exploratory endpoint, the influence of breast density and tumor size on tumor detection will be investigated. Results Recruitment began in November 2018 and was completed by March 2020. We anticipate the preliminary results to be available by summer 2021. Conclusions This study will provide insights on the diagnostic accuracy of microwave breast imaging using a rotational bistatic impulse radar. The collected data will improve the diagnostic algorithm of microwave imaging and lead to enhanced device performance. Trial Registration Japan Registry of Clinical Trials jRCTs062180005; https://jrct.niph.go.jp/en-latest-detail/jRCTs062180005 International Registered Report Identifier (IRRID) DERR1-10.2196/17524

Decreased level of peripheral CD8+CD28+ T cells is associated with lymph node metastasis in patients with breast cancer

2020 ◽  
Vol 16 (32) ◽  
pp. 2611-2617
Author(s):  
Yalun Li ◽  
Tianyi Qian ◽  
Hengqiang Zhao ◽  
Zhen Zhang ◽  
Yue Ming ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Breast Tumors ◽  
Peripheral Lymphocyte ◽  
Cytotoxic T Cell ◽  
Benign Tumors ◽  
Surrogate Markers ◽  
Potential Therapeutic Target ◽  
Node Metastasis

Background: Lymph node metastasis (LNM) is an independent risk factor for prognosis in patients with early breast cancer (EBC). Here we explored whether peripheral lymphocyte subtypes could be used as surrogate markers for LNM in patients with EBC. Materials & methods: The lymphocyte subpopulations in peripheral blood were measured in 152 EBC patients and 43 patients with benign breast tumors. Results: The cytotoxic T cell count was significantly lower in patients with EBC than in patients with benign tumors (244.17 ± 105.83 vs 289.97 ± 121.72; p = 0.02), especially in patients with LNM (218.36 ± 86.21; p = 0.04). Conclusion: A decreased level of peripheral CD8+CD28+ T lymphocytes is associated with LNM in patients with EBC and could be used as a potential therapeutic target for breast cancer.

scholarly journals A comparison of mammography, ultrasonography, and far-infrared thermography with pathological results in screening and early diagnosis of breast cancer

2014 ◽  
Vol 8 (1) ◽  
pp. 11-19 ◽  
Author(s):  
Xiaoli Yao ◽  
Wen Wei ◽  
Juanjuan Li ◽  
Lijun Wang ◽  
ZhiLiang Xu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Diagnostic Accuracy ◽  
Infrared Thermography ◽  
Breast Imaging ◽  
Early Stage ◽  
Large Population ◽  
Screening Method ◽  
Far Infrared ◽  
Pathological Examination

Abstract Background: Many breast-imaging techniques have been developed as primary clinical methods for identifying early-stage breast cancers and differentiating them from benign breast tumors. For the large population of China, any screening method that is rapid, economical, and accurate is worthy of evaluation. Objective: To compare the effectiveness of mammography, color Doppler ultrasonography, and far-infrared thermography in the screening and early diagnosis of breast cancer. Methods: Data from 2036 women with breast disease between January 2007 and May 2011 were included in this study. All patients underwent mammography, ultrasonography, and far-infrared thermography imaging. The diagnostic accuracy of the three methods was determined using postoperative pathological results as the diagnostic criterion standard. Results: There were 480 patients found to have breast malignancies on pathological examination. The lesion diameter was <2 cm in 853 cases. Among them, breast cancer was found in 73 patients and carcinoma in situ in 22 patients. There was no difference in the accuracy of mammography and ultrasonography (96.1% versus 95.8%). However, there were significant differences between the accuracy of far-infrared thermography (97.1%) and ultrasonography and mammography. The sensitivity and specificity of far-infrared thermography was superior to that of mammography and ultrasonography in lesions <2 cm in diameter. Conclusion: Far-infrared thermography is more accurate for breast cancer screening than ultrasonography and mammography for lesions <2 cm. It has comparable diagnostic accuracy to ultrasound and better diagnostic accuracy than mammography for lesions >2 cm in diameter.

Microwave Breast Imaging: experimental tumour phantoms for the evaluation of new breast cancer diagnosis systems

2018 ◽  
Vol 4 (2) ◽  
pp. 025036 ◽  
Author(s):  
Bárbara L Oliveira ◽  
Declan O’Loughlin ◽  
Martin O’Halloran ◽  
Emily Porter ◽  
Martin Glavin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Breast Imaging ◽  
Breast Cancer Diagnosis ◽  
Experimental Tumour ◽  
Microwave Breast Imaging

Hybrid PET-MRI of the breast: A promising tool for the characterization of breast tumors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10570-10570
Author(s):  
Katja Pinker-Domenig ◽  
Hubert Bickel ◽  
Wolfgang Bogner ◽  
Heinrich Magometschnigg ◽  
Stephan Gruber ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Standard Dose ◽  
Breast Mri ◽  
Breast Tumors ◽  
Blood Pool ◽  
Imaging Data ◽  
Glucose Levels ◽  
Promising Tool ◽  
Pet Ct

10570 Background: To evaluate if PET-MRI of breast tumors improves staging of breast cancer and obviates unnecessary breast biopsies. Methods: 106 patients with breast tumors detected by mammography or ultrasound and classified as BIRADS 3-5 were included in this IRB approved prospective study. All patients were examined with dedicated 18FDG-PET-CT and 3T multiparametric MRI of the breast. Examinations were scheduled no longer than 7 days apart. MRI protocol included: a diffusion-weighted sequence (DWI), a T2-w sequence and a contrast-enhanced combined high temporal and spatial resolution 3D-T1-w sequence before and after application of a standard dose Gd-DOTA. For PET-CT patients fasted at least 6 h before injection of approx. 300 MBq 18F-FDG based on the patients weight. Scanning was started 45 min after injection. Blood glucose levels were <150 mg/dl. A prone PET dataset over the breasts was acquired using a positioning device allowing the same patient geometry as the breast MRI coil. CT data was used for attenuation correction. Co-registration of imaging data and image fusion were performed. PET-MRI was assessed for lesion morphology and EH-kinetics according to BI-RADS and restricted diffusivity with an ADC threshold 1.25 x10-3mm2/s set as the cut-off for malignancy. Lesions were assed for 18F-FDG–avidity and classified as positive when 18F-FDG-uptake was greater than blood-pool activity. Additionally, nodal status was recorded for each technique and patient. Histopathology was used as the standard of reference. Results: PET-MRI achieved an excellent sensitivity of 100%. Specificity was increased from 68% to 80% as compared to routinely used MRI. Diagnostic accuracy of PET-MRI for diagnosis of breast cancer was 95%. PET-MRI would have obviated unnecessary breast biopsies in 80% of benign breast lesions without missing any cancers. Additionally, PET-MRI increased sensitivity in the detection of lymphnode metastases from 70% to 87% compared to MRI alone. Conclusions: With PET-MRI unnecessary breast biopsies can be obviated without missing any cancers. PET-MRI increases overall diagnostic accuracy in the diagnosis of breast cancer and lymphnode metastases for an accurate staging.

Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers

2020 ◽  
Vol 86 (10) ◽  
pp. 1243-1247
Author(s):  
Abigail Fong ◽  
Ilana Cass ◽  
Catherine John ◽  
Jessica Gillen ◽  
Kathleen M. Moore ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Breast Imaging ◽  
Early Stage ◽  
Brca Mutation ◽  
Retrospective Chart Review ◽  
Cancer Surveillance ◽  
Mutation Carriers ◽  
Institutional Review ◽  
Brca Mutation Carriers

BRCA1 or 2 mutations result in higher cancer risk for breast cancer (BC) and epithelial ovarian cancer (EOC) for carriers than exists in the general population. Optimal breast imaging surveillance in these patients has not been well defined. An Institutional Review Board-approved, multi-institutional retrospective chart review was performed. Patients diagnosed with BRCA-associated EOC between 1990-2015 were identified; demographic and clinical data were collected and analyzed. 192 BRCA mutation–positive patients with EOC were identified. 16/192 (8.3%) women were diagnosed with BC following EOC, at a median of 50 (range 5-327) months following EOC diagnosis and median age 59.5 (45-84) years. Breast cancer was most commonly detected on mammogram 7/16 (44%) or clinical exam 7/16 (44%). 2/16 (12.5%) had occult BC found during risk-reducing mastectomy. 14 (88%) had early-stage (0-2) disease. At mean follow-up of 8.1 years, 6 (37.5%) patients with BC following EOC had died due to EOC. The risk of BC diagnosis following EOC in BRCA mutation carriers is low; most of these BCs are early stage and diagnosed with mammography or physical exam. Overall, survival in BRCA mutation carriers is dominated by EOC-related mortality. Breast cancer surveillance in BRCA mutation carriers following EOC should prioritize nonsurgical strategies.

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.

1996 ◽  
Vol 14 (6) ◽  
pp. 1848-1857 ◽  
Author(s):  
N Avril ◽  
J Dose ◽  
F Jänicke ◽  
S Bense ◽  
S Ziegler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pet Imaging ◽  
Breast Imaging ◽  
Breast Tumors ◽  
Partial Volume Correction ◽  
Partial Volume ◽  
Volume Correction ◽  
Fdg Uptake ◽  
Significant Difference ◽  
Malignant Breast

PURPOSE To evaluate the diagnostic value of position emission tomographic (PET) imaging with F-18 fluorodeoxyglucose (FDG) in differentiating between benign and malignant breast tumors. PATIENTS AND METHODS Fifty-one patients, with suspicious breast lesions newly discovered either by physical examination or by mammography, underwent PET imaging before exploratory surgery. FDG-PET images of the breast were analyzed visually and quantitatively for objective assessment of regional tracer uptake. RESULTS Primary breast cancer was identified visually with a sensitivity of 68% to 94% and a specificity of 84% to 97% depending on criteria used for image interpretation. Quantitative analysis of FDG uptake in tumors using standardized uptake values (SUV) showed a significant difference between benign (1.4 +/- 0.5) and malignant (3.3 +/- 1.8) breast tumors (P < .01). Receiver operating characteristic (ROC) curve analysis exhibited a sensitivity of 75% and a specificity of 100% at a threshold SUV value of 2.5. Sensitivity increased to 92% with a corresponding specificity of 97% when partial volume correction of FDG uptake was performed based on independent anatomic information. CONCLUSION PET imaging allowed accurate differentiation between benign and malignant breast tumors providing a high specificity. Sensitivity for detection of small breast cancer ( < 1 cm) was limited due to partial volume effects. Quantitative image analysis combined with partial volume correction may be necessary to exploit fully the diagnostic accuracy. PET imaging may be helpful as a complimentary method in a subgroup of patients with indeterminate results of conventional breast imaging.

scholarly journals Prioritizing breast imaging services during the COVID pandemic: A survey of breast imaging facilities within the Breast Cancer Surveillance Consortium

2021 ◽  
Vol 151 ◽  
pp. 106540
Author(s):  
Brian L. Sprague ◽  
Ellen S. O'Meara ◽  
Christoph I. Lee ◽  
Janie M. Lee ◽  
Louise M. Henderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Imaging ◽  
Cancer Surveillance ◽  
Breast Cancer Surveillance Consortium

Detection of early breast cancer beyond mammographic screening: a promising biomarker panel

2019 ◽  
Vol 13 (13) ◽  
pp. 1107-1117 ◽  
Author(s):  
Moritz Hamann ◽  
Sabine Grill ◽  
Joachim Struck ◽  
Andreas Bergmann ◽  
Oliver Hartmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Breast Imaging ◽  
Human Growth ◽  
Mammographic Screening ◽  
Precise Determination ◽  
Cancer Surveillance ◽  
Individual Risk ◽  
Biomarker Panel ◽  
Individual Risk Assessment

Aim: We assessed the suitability of a biomarker panel to improve early detection and individual risk assessment in breast cancer (BC) patients. Materials & methods: PENK, pro-SP, hGH and CA15-3 of 204 BC patients and 68 healthy controls were measured. Results: PENK and human growth hormone concentrations were significantly lower and pro-SP values higher in BC patients compared with controls. C-index increased from 0.628 for CA15-3 alone to 0.754 when all three biomarkers were added to the model. Conclusion: This biomarker panel may improve early detection of BC and influence the assessment of breast imaging. It might be useful for a risk-adapted cancer surveillance or primary prevention program by a more precise determination of an individualized BC risk.

Sign in / Sign up

Export Citation Format

Share Document